CN1634945A - Synthesis of oxaliplatin - Google Patents
The invention relates to synthesis and preparation of an antitumor drug oxaliplatin. Background Oxaliplatin is a platinum group metal complex, which is a new generation of platinum...
Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based …
2018年6月26日 · In recent years, fluorine-containing organic drugs have already been applied in a broad range of therapeutic areas. Herein, we report our attempt to introduce an axial fluorine ligand to Pt(IV) complexes by oxidizing oxaliplatin with electrophilic fluorinating reagents in different protic solvents.
CN1837223A - Novel process for synthesis of oxaliplatin as anticancer ...
The invention relates to a novel synthesis process of oxaliplatin (oxaliplatin) which is a platinum anticancer drug, and belongs to the field of biological pharmacy. Background
Synthesis, crystal structure and cytotoxicity of new oxaliplatin ...
Synthesis, crystal structure and cytotoxicity of new oxaliplatin analogues indicating that improvement of anticancer activity is still possible
Solid-phase synthesis of oxaliplatin–TATpeptide bioconjugates
In this work, a TAT-peptide fragment (YGRKKRRQRRR) was for the first time conjugated to a platinum(IV) analog of oxaliplatin as a vehicle for membrane penetration.
Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum ...
2018年7月16日 · Herein, we report our attempt to introduce an axial fluorine ligand to Pt(IV) complexes by oxidizing oxaliplatin with electrophilic fluorinating reagents in different protic solvents. The crystal structure of one representative complex is presented.
Synthesis and structure-activity relationships of mono- and …
2005年11月1日 · Recently, 4-alkyl substituted oxaliplatin derivatives have been synthesized in our group, and a comparison of their cytotoxicity strongly indicated that improvement of the anticancer activity of oxaliplatin is feasible.
Synthesis, Characterization, and Cytotoxicity of the First Oxaliplatin ...
2016年6月25日 · Synthesis, Characterization, and Cytotoxicity of the First Oxaliplatin Pt(IV) Derivative Having a TSPO Ligand in the Axial Position by Salvatore Savino
Oxaliplatin (Eloxatin+, Sanofi-Synthelabo) was first approved in 1998 in France and subsequently in the rest of Europe and, more recently, in 2002 by the Food and Drug Administration in the United States.
Oxaliplatin and its derivatives – An overview - ScienceDirect
2023年12月15日 · As early as 2010 there were signs that oxaliplatin could inhibit ribosome biogenesis as rRNA transcription inhibition and a reduction in 47S rRNA synthesis at clinically relevant concentrations were noted, but it wasn’t until 7 years later that a direct link was made to mechanism of action.